Catalent Biologics Content
-
Premier European Product Launch And Packaging Solution
10/18/2023
Learn how Catalent Biologics is poised to advance your product with speed. Leverage our robust filling lines and proven expertise in commercial manufacturing to successfully deliver your critical medicines.
-
Secondary Packaging Strategies For Commercial Launch Of A Biologic
8/17/2022
A commercial packaging solution can be the first and enduring impression that a sponsor company makes on a patient, and its suitability can impact a biologic’s commercial success.
-
Rapid Global Characterization Of Ig G1 Following Oxidative Stress
11/22/2019
Review a method for rapid and consistent global characterization of leachable metals- or peroxide-stressed immunoglobulin (Ig) G1 monoclonal antibodies (mAbs).
-
High-Throughput Preformulation Development Platform For Biologics
11/21/2019
A high-throughput formulation development for sample preparation and sample analysis enabled a simple and less labor-intensive screening of a broad range of conditions in considerably less time.
-
Analytical Quality By Design Using Design Of Experiments
11/21/2019
Design of Experiment (DoE) is the centerpiece of analytical Quality by Design. A DoE assay development pipeline approach delivers optimized, robust, and rugged analytical methods ready for method qualification.
-
Strategies To Achieve Successful Approval & Launch
11/18/2019
Four experts share how scale-up, regulatory expectations, demand forecasting, and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey.
-
Standardizing Process Characterization And Late Phase Development
11/18/2019
Learn an approach for process characterization to produce a monoclonal antibody, specifically at the drug substance biomanufacturing step, to improve efficiency and effectiveness.
-
Characterization Of A Therapeutic mAb, Associated Antigen-Binding Fragments
10/9/2019
Determining size homogeneity of a mAb in solution is important for comparability and characterization. For this study, an IgG1 antibody was cleaved into antigen-binding fragments using pepsin and papain digestion respectively, followed by Protein A purification.
-
Intensified Fed-Batch Process Using N-1 Perfusion And ambr 15
10/9/2019
Learn how to combine N-1 perfusion with the ambr®15 bioreactor system to create a powerful tool for rapid development of a highly efficient cell culture process.
-
Ensuring Success In Early Biopharmaceutical Formulation Development
6/10/2019
Biopharmaceuticals tend to be highly unstable. A pilot formulation study at the early drug substance development stage can make things considerably easier at the manufacturing stage.